MingMed Biotechnology Announces Successful Completion of Phase I/II Clinical Trials in China for YY001, the World’s First Recombinant Botulinum Toxin Type A

MingMed Biotechnology Co., Ltd. (hereinafter referred to as "MingMed") announced that YY001, the injectable recombinant botulinum toxin type A independently developed by its holding company, Chongqing Yuyan Pharmaceutical Co., Ltd. (hereinafter referred to as "Yuyan Pharmaceutical"), has successfully completed Phase I/II clinical trials for the indication of improving moderate to severe glabellar lines and is actively preparing for Phase III clinical trials.

Dr. Wu Yang, Chief Scientific Officer of MingMed, introduced: "YY001 is the world's first recombinant botulinum toxin type A independently developed and entered into clinical trials in China. Through independent innovation, we have achieved comprehensive breakthroughs in science, technology, engineering, production, and management, and own independent and complete intellectual property rights. YY001 has successfully concluded the Phase I/II multi-center clinical trial in China, and held a clinical summary meeting on May 20, 2023, in Chongqing. Based on the trial results disclosed at the clinical research summary meeting, we are very satisfied with the safety and efficacy data of YY001. We have full confidence in YY001."

Mr. Liu Miao, Chief Operating Officer of MingMed and Chief Executive Officer of Yuyan Pharmaceutical, stated: "Botulinum toxin drugs have extensive applications in multiple medical treatment fields, with a huge market scale both in China and globally, and are in a phase of rapid growth. The new-generation recombinant Type A botulinum toxin YY001 is an important pipeline product under MingMed, and the successful completion of its Phase I/II clinical trials has laid a significant foundation for the subsequent development of this product and the enhancement of MingMed's corporate value. We will fully advance the Phase III clinical trial of YY001 and conduct more clinical studies on additional indications across various medical fields, contributing to human health with a new generation of high-quality, globally competitive, China-produced drugs."

MingMed Biotechnology Co., Ltd. is a Chinese enterprise focused on the independent research and development of innovative drugs with global competitiveness. The company boasts a research and development team led by several world-renowned scientists and experts. Leveraging our R&D capabilities and efficient operational abilities, we have independently developed a diversified and synergistic product pipeline, including ophthalmic drugs, recombinant protein botulinum toxins, tumor immunotherapy drugs, and pet immunotherapy drugs. This includes multiple potential first-in-class innovative drugs, and all major products have entered the clinical stage.